論文種別	原著(症例報告除く)
言語種別	英語
査読の有無	その他(不明)
表題	Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study.
掲載誌名	正式名：Dermatology and therapy 略　 称：Dermatol Ther (Heidelb) ISSNコード：21938210
著者・共著者	Toshiyuki Yamamoto, Hideaki Tanizaki, Kenshi Yamasaki, Naoko Matsubara, Masahiko Nakayama, Eri Iwashita, Keiichi Yamanaka
発行年月	2026/05
概要	INTRODUCTION:Pyoderma gangrenosum (PG) is a rare, autoinflammatory skin disorder characterized by painful ulcers, with scarce treatment options. Adalimumab is a recently approved tumor necrosis factor-alpha inhibitor for PG, for which real-world data remain limited. This study evaluated the long-term safety and effectiveness of adalimumab in patients with PG.METHODS:This multicenter, prospective, open-label, single-arm, postmarketing observational study enrolled patients with PG who were prescribed adalimumab and were monitored for 52 weeks. The primary outcome was safety, assessed as the incidence proportion of infections reported as adverse drug reactions (ADRs). Secondary outcomes included other safety measures and effectiveness, estimated using the Physician Global Assessment (PGA), Investigator Inflammation Assessment, and Verbal Rating Scale (VRS) for pain. Relapse rates after remission and changes in PG subtype during the observation period were also examined.RESULTS:Sixty-seven patients with PG were enrolled in the study. The mean age was 61.9 years, and 77.6% of the patients had comorbidities, including diabetes mellitus (19.4%), ulcerative colitis (16.4%), and hypertension (14.9%); 59.7% were concomitantly receiving systemic steroids. The PG subtypes among the enrolled patients were ulcerative (n = 62), pustular (n = 2), vegetative (n = 2), and bullous (n = 1). The incidence proportions of infections reported as ADRs and serious ADRs were 14.9% and 9.0%, respectively. The proportions of patients with a PGA score (total lesions) of 0/1 at weeks 12, 26, and 52 were 36.0%, 46.2%, and 57.7%, respectively, and with a VRS score of 0 at weeks 26 and 52 were 45.7% and 52.4%, respectively. No relapses occurred among patients who discontinued treatment due to symptom improvement.CONCLUSIONS:This real-world study demonstrated no new safety concerns with adalimumab and demonstrated its effectiveness, including pain relief, across a heterogeneous PG population. These findings support its use as a standard treatment for PG, including in patients receiving concomitant systemic steroid therapy.TRIAL REGISTRATION:ClinicalTrials.gov identifier, NCT04750213.
DOI	10.1007/s13555-026-01772-4
PMID	42107018